


**IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**



<p>ENDO PHARMACEUTICALS INC. and GRÜNENTHAL GMBH,</p> <p style="text-align: center;">Plaintiffs,</p> <p>v.</p> <p>AMNEAL PHARMACEUTICALS, LLC and AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,</p> <p style="text-align: center;">Defendants.</p>	<p style="text-align: center;">C.A. No. 12-cv-08115-TPG-GWG</p>
<p>ENDO PHARMACEUTICALS INC. and GRÜNENTHAL GMBH,</p> <p style="text-align: center;">Plaintiffs,</p> <p>v.</p> <p>TEVA PHARMACEUTICALS USA, INC., and BARR LABORATORIES, INC.,</p> <p style="text-align: center;">Defendants.</p>	<p style="text-align: center;">C.A. No. 12-cv-08060-TPG-GWG</p>
<p>ENDO PHARMACEUTICALS INC. and GRÜNENTHAL GMBH,</p> <p style="text-align: center;">Plaintiffs,</p> <p>v.</p> <p>IMPAX LABORATORIES, INC. and THORX LABORATORIES, INC.,</p> <p style="text-align: center;">Defendants.</p>	<p style="text-align: center;">C.A. No. 12-cv-08317-TPG-GWG</p>
<p>ENDO PHARMACEUTICALS INC.,</p> <p style="text-align: center;">Plaintiff,</p> <p>v.</p> <p>ACTAVIS INC. and ACTAVIS SOUTH ATLANTIC LLC,</p> <p style="text-align: center;">Defendants.</p>	<p style="text-align: center;">C.A. No. 12-cv-08985-TPG-GWG</p>

<p>ENDO PHARMACEUTICALS INC. and GRÜNENTHAL GMBH,</p> <p>Plaintiffs,</p> <p>v.</p> <p>IMPAX LABORATORIES, INC.,</p> <p>Defendant.</p>	<p>C.A. No. 13-cv-00435-TPG-GWG</p>
<p>ENDO PHARMACEUTICALS INC. and GRÜNENTHAL GMBH,</p> <p>Plaintiffs,</p> <p>v.</p> <p>ACTAVIS INC., ACTAVIS SOUTH ATLANTIC LLC, and WATSON PHARMACEUTICALS, INC.,</p> <p>Defendants.</p>	<p>C.A. No. 13-cv-00436-TPG-GWG</p>
<p>ENDO PHARMACEUTICALS INC.,</p> <p>Plaintiff,</p> <p>v.</p> <p>ROXANE LABORATORIES, INC.,</p> <p>Defendant.</p>	<p>C.A. No. 13-cv-03288-TPG</p>
<p>ENDO PHARMACEUTICALS INC.,</p> <p>Plaintiff,</p> <p>v.</p> <p>RANBAXY LABORATORIES LTD., RANBAXY INC., AND RANBAXY PHARMACEUTICALS INC.,</p> <p>Defendants.</p>	<p>C.A. No. 13-cv-04343-TPG</p> <p>C.A. No. 13-cv-08597-TPG</p>

SECOND STIPULATION AND ORDER
REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216

Whereupon plaintiff Endo Pharmaceuticals Inc. (“Endo”) and defendants Actavis Inc., Actavis South Atlantic LLC, and Watson Pharmaceuticals, Inc. (collectively, “Actavis”); Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC (collectively, “Amneal”); Impax Laboratories, Inc. (“Impax”); Ranbaxy Laboratories Ltd., Ranbaxy Inc., and Ranbaxy Pharmaceuticals Inc. (collectively, “Ranbaxy”); Roxane Laboratories, Inc. (“Roxane”); Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc. (collectively, “Teva”); and ThoRx Laboratories, Inc. (“ThoRx”) (collectively “Defendants”) wish to narrow the issues for trial, they make the following stipulation:

The parties further stipulate and agree as follows:


1. As used in the asserted claims of U.S. Patent 8,329,216 (“the ’216 patent”), the term “a release rate profile designed to provide adequate blood plasma levels” over at least 12 hours should be construed to mean “a release rate profile that provides adequate blood plasma levels” over at least 12 hours.

2. In light of this agreed-upon construction, Defendants stipulate and agree that each of their ANDA tablets has “a release rate profile designed to provide adequate blood plasma levels” over at least 12 hours. Accordingly, paragraph 3 on page 3 of the “STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216” dated March 27, 2015 is deleted because that issue is no longer disputed by Defendants, and Endo is not required to present proof that the Defendants’ ANDA tablets satisfy that limitation.

Endo and Defendants have entered this second stipulation as part of their continued good faith efforts to narrow the issues for trial. Endo and Defendants agree that they will not use this second stipulation as a basis for any claim, allegation, or assertion that any party has not sufficiently narrowed the issues of infringement and validity or not acted in good faith throughout that process.

Stipulated and agreed:

DATED: April 8, 2015



Jonathan D. Loeb

Jeffrey Fisher

DECHERT LLP

2440 W. El Camino Real, Suite 700

Mountain View, CA 94040

(650) 813-4800

jonathan.loeb@dechert.com

jeffrey.fisher@dechert.com

Martin J. Black

Robert D. Rhoad

Sharon K. Gagliardi

DECHERT LLP

Cira Centre

2929 Arch Street

Philadelphia, PA 19104

(215) 944-4000

martin.black@dechert.com

robert.rhoad@dechert.com

sharon.gagliardi@dechert.com

Attorneys for Plaintiff

Endo Pharmaceuticals, Inc.



Alan B. Clement

Paul Sudentas

LOCKE LORD LLP

3 World Financial Center

New York, NY 10281

Scott B. Feder

Keith D. Parr

Myoka Kim Goodin

Amanda K. Kelly

Wasim K. Bleibel

Nina Vachhani


LOCKE LORD LLP

111 South Wacker Drive

Chicago, IL 60606

Attorneys for Defendant

Roxane Laboratories, Inc.



Elizabeth Holland
Huiya Wu
Daniel P. Margolis
Brian J. Robinson
GOODWIN PROCTER LLP
The New York Times Building
New York, NY 10018-1405
Tel: (212) 459-7287
Fax: (212) 355-3333
eholland@goodwinprocter.com
hwu@goodwinprocter.com
dmargolis@goodwinprocter.com
brobinson@goodwinprocter.com


*Attorneys for Defendants
Teva Pharmaceuticals USA, Inc., and
Barr Laboratories, Inc.*



William R. Zimmerman
Andrea L. Cheek
**KNOBBE, MARTENS, OLSON & BEAR
LLP**
1717 Pennsylvania Avenue, Suite 900
Washington, DC 20006
(202) 640-6400
bill.zimmerman@knobbe.com
andrea.cheek@knobbe.com

Carol Pitzel Cruz
**KNOBBE, MARTENS, OLSON & BEAR
LLP**
925 Fourth Ave, Suite 2500
Seattle, WA 98104
206 405-2000
2cmp@kmob.com


*Attorneys for Defendants
Ranbaxy Laboratories, LTD., Ranbaxy Inc.,
and Ranbaxy Pharmaceuticals, Inc.*



Scott R. Samay
WINSTON & STRAWN LLP
200 Park Avenue
New York, NY 10166
(212) 294-6700
ssamay@winston.com

Maureen L. Rurka
Kevin Warner
WINSTON & STRAWN LLP
35 West Wacker Drive
Chicago, IL 60601
(312) 558-5600
mrurka@winston.com
kwarner@winston.com

*Attorneys for Defendants
Impax Laboratories, Inc. and
ThoRx Laboratories, Inc.*



Charles A. Weiss
Howard S. Suh
Eric H. Yecies
Nicholas P. Chiara
HOLLAND & KNIGHT LLP
31 West 52nd Street
New York, NY 10019
Tel: (212) 513-3200
Fax: (212) 385-9010
charles.weiss@hklaw.com
howard.suh@hklaw.com
eric.yecies@hklaw.com
nicholas.chiara@hklaw.com

*Attorneys for Defendants
Actavis, Inc., Actavis South Atlantic LLC and
Watson Pharmaceuticals, Inc.*

Keeto Sabharwal *UE*

H. Keeto Sabharwal
Paul A. Ainsworth (*admitted pro hac vice*)
Uma N. Everett (*admitted pro hac vice*)
Dennies Varughese (*admitted pro hac vice*)
Rami Bardenstein
Krishan Y. Thakker
Andrew M. Nason (*admitted pro hac vice*)
Brett E. Howard


**STERNE, KESSLER, GOLDSTEIN &
FOX PLLC**

1100 New York Avenue, NW
Washington, DC 20005
Telephone No.: (202) 371-2600
Facsimile No.: (202) 371-2540
keetos@skgf.com
painsworth@skgf.com
ueverett@skgf.com
dvarughe@skgf.com
rbardenstein@skgf.com
anason@skgf.com
kthakker@skgf.com
bhoward@skgf.com

*Attorneys for Defendants
Amneal Pharmaceuticals, LLC and
Amneal Pharmaceuticals of New York, LLC*

SO ORDERED:

This 7th day of April, 2015



**HONORABLE THOMAS P. GRIESA
UNITED STATES DISTRICT JUDGE**